Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection

16. november 2026 opdateret af: Qian Chu, Tongji Hospital

An Exploratory Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of Autologous Tumor-Infiltrating Lymphocyte (TIL) Infusion for the Treatment of Recurrent/Metastatic Lung Cancer or Cervical Cancer in Previously Treated Patients.

This study is a single - center, single - arm, open - label, single - dose, dose - escalation exploratory study. The main purpose is to evaluate the safety and tolerability of autologous tumor - infiltrating lymphocyte injection in the treatment of recurrent or metastatic lung cancer or cervical cancer. Meanwhile, it will also preliminarily explore the effectiveness, PK characteristics, PD characteristics and changes in immune - related parameters of autologous tumor - infiltrating lymphocyte injection in subjects with recurrent or metastatic lung cancer or cervical cancer.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

18

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Hubei
      • Wuhan, Hubei, Kina, 430030

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • 1.The patient voluntarily signs the informed consent form and is able to complete the study procedures, follow-up examinations and treatments.
  • 2.Aged 18 to 75 years old, regardless of gender.
  • 3.Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
  • 4.Patients with pathologically confirmed recurrent or metastatic malignant lung cancer or cervical cancer (confirmed by cytology or histopathology) who have failed or are intolerant to standard treatment, or have no standard treatment plan.
  • 5.The subject has at least one eligible tumor lesion/tissue for TIL preparation.
  • 6.After TIL sampling and excisional biopsy, the subject must have at least one measurable tumor lesion in accordance with the RECIST 1.1 criteria.
  • 7.Expected survival time > 6 months.
  • 8.Sufficient hematological and end-organ function as defined by the following laboratory test results, which must be completed within 7 days before TIL tumor tissue collection: Routine blood test: White blood cell count ≥ 2.5×10⁹/L; Absolute neutrophil count (ANC) ≥ 1.5×10⁹/L; Absolute lymphocyte count (ALC) ≥ 0.7×10⁹/L; Platelet (PLT) ≥ 100×10⁹/L; Hemoglobin (HGB) ≥ 90g/L; Coagulation function: International normalized ratio (INR) ≤ 1.5×ULN, unless anticoagulant therapy was received within the previous 7 days; Activated partial thromboplastin time (APTT) ≤ 1.5×ULN, unless anticoagulant therapy was received within the previous 7 days; Renal function: Serum creatinine ≤ 1.5mg/dL (or 132.6μmol/L) or creatinine clearance ≥ 60mL/min; Urine protein < 2+ in routine urine test, or 24-hour urine protein quantification < 1g; Liver function: Aspartate aminotransferase (AST/SGOT) ≤ 3×ULN; Alanine aminotransferase (ALT/SGPT) ≤ 3×ULN; Total bilirubin (TBIL) ≤ 1.5×ULN. Note: For patients with liver metastasis or primary liver tumor lesions, AST and ALT must be ≤ 5×ULN; For patients with a history of Gilbert's syndrome or suspected of having the disease, TBIL must be ≤ 3×ULN.
  • 9.Toxic reactions caused by previous treatment (excluding disease-related ones) have recovered to ≤ Grade 1 before enrollment (excluding alopecia and ≤ Grade 2 neurotoxicity caused by chemotherapy drugs).
  • 10.Women of childbearing age must have a negative serum pregnancy test within 7 days before enrollment. Any male or female patient of childbearing potential must agree to use effective contraceptive methods from enrollment until at least 6 months after TIL cell infusion. A patient is considered to have childbearing potential as judged by the investigator if he/she is biologically capable of having children and has normal sexual activity. Female patients without childbearing potential must meet at least one of the following criteria: Has undergone hysterectomy or bilateral oophorectomy; Medically confirmed ovarian failure; Medically confirmed postmenopause (at least 12 consecutive months of amenorrhea).
  • 11.Able to comply with the study protocol as judged by the investigator.

Exclusion Criteria:

  • 1.Patients with only bone metastatic lesions or central nervous system metastatic lesions.
  • 2.Patients who have previously received any adoptive cell therapy.
  • 3.Patients who have received any systemic anti-tumor treatment (including chemotherapy, radiotherapy, molecular targeted therapy, etc.) within 4 weeks before preconditioning.
  • 4.Patients who have received systemic corticosteroid therapy for immunosuppression (≥10mg/day, excluding inhaled therapy, local therapy or physiological replacement therapy) or other immunosuppressive drug therapy within 2 weeks before preconditioning.
  • 5.Patients who have undergone major surgery deemed unsuitable for enrollment by the investigator within 4 weeks before screening, or plan to undergo other major surgeries (excluding the planned surgery for TIL cell preparation as specified in the protocol) during the study period.
  • 6.Patients with other malignant tumors within 5 years before screening or at the same time (excluding patients with locally treated malignant tumors who do not require treatment for more than 1 year and have no significant recurrence risk as judged by the investigator).
  • 7.Patients with active or suspected autoimmune or inflammatory diseases (including but not limited to rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, autoimmune hemolytic anemia, scleroderma, systemic lupus erythematosus, Wegener's granulomatosis, ulcerative colitis, Crohn's disease, etc.).
  • 8.Patients with a history of organ transplantation or hematopoietic stem cell transplantation.
  • 9.Patients with any of the following infections: Hepatitis B (positive for hepatitis B surface antigen [HbsAg] and/or hepatitis B core antibody [HbcAb]; patients with HBVDNA < 1000 copies/ml are eligible for enrollment); Hepatitis C (positive for HCV antibody test and positive for HCV-RNA test); Patients with systemic active infections requiring antibiotic treatment (e.g., sepsis, acteremia, fungemia, etc.); Patients with congenital or acquired immunodeficiency (including but not limited to severe combined immunodeficiency disease, patients with HIV infection, etc.); Patients positive for TP antibody or HTLV-1 antibody.
  • 10.Patients who have received live vaccines or attenuated vaccines within 4 weeks before preconditioning.
  • 11.Patients with symptomatic and/or untreated brain metastases (patients whose symptoms are stable for ≥14 days after clear treatment before preconditioning may be considered for enrollment).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Autologous Tumor-Infiltrating Lymphocyte Injection

Autologous Tumor-Infiltrating Lymphocyte Injection with a single administration dose of 1×10¹⁰ (±20%), 3×10¹⁰ (±20%), and 5×10¹⁰ (±20%) cells per person per administration respectively.

DK008

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
ORR
Tidsramme: Up to 12 months after first dose

Objective Response Rate (ORR) is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) to treatment, as assessed by imaging or clinical criteria. Tumor response is typically evaluated using standardized criteria such as the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Up to 12 months after first dose

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
PFS
Tidsramme: From date of first study treatment until the date of first documented disease progression or death from any cause, whichever comes first, assessed up to 36 months.

Progression-Free Survival (PFS) is defined as the time from the date of randomization (or initiation of treatment) to the date of disease progression or death from any cause, whichever occurs first. Disease progression is assessed according to standardized criteria such as RECIST version 1.1

From date of first study treatment until the date of first documented disease progression or death from any cause, whichever comes first, assessed up to 36 months.
DOR
Tidsramme: From date of first study treatment until the date of first documented disease progression or death from any cause, whichever comes first, assessed up to 36 months.

Duration of Response (DOR) is defined as the time from the first documented evidence of a complete response (CR) or partial response (PR) until the date of disease progression or death from any cause, whichever occurs first. Tumor responses are assessed based on standardized criteria such as RECIST version 1.1.

From date of first study treatment until the date of first documented disease progression or death from any cause, whichever comes first, assessed up to 36 months.
OS
Tidsramme: From date of first study treatment until the date of death from any cause, whichever comes first, assessed up to 60 months.

Overall Survival (OS) is defined as the time from the date of randomization (or initiation of treatment) to the date of death from any cause.

From date of first study treatment until the date of death from any cause, whichever comes first, assessed up to 60 months.

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
T Cell Subsets Associated with Pharmacokinetics
Tidsramme: Within 30min before TIL infusion in day0, and Day1±1 hours, Day2±2 hours, Day4±1 day, Day7±1 day, Day14±1 day,Day21±1 day, Day28±1 day, Day42±3 days post TIL infusion

Pharmacokinetic (PK) assessments were conducted to evaluate the absorption, distribution, metabolism, and excretion of the study drug. Immunophenotyping of T cell subsets associated with study drug pharmacokinetics. Measurements include absolute cell counts, relative percentages, and percentage change from baselin.

Within 30min before TIL infusion in day0, and Day1±1 hours, Day2±2 hours, Day4±1 day, Day7±1 day, Day14±1 day,Day21±1 day, Day28±1 day, Day42±3 days post TIL infusion
PD-Related T Cell Subsets
Tidsramme: Within 30 minutes prior to TIL infusionin Day0, Day14±1 day, Day28±1 day, Day42±3 days,Day84±3 days, Day126±3 days, Day168±3 days after TIL infusion, and at early withdrawal visit.

Pharmacodynamic (PD) assessments were performed to evaluate the biological effects and mechanism of action of the study drug. Immunophenotyping of efficacy-associated T cell subsets by flow cytometry.

Within 30 minutes prior to TIL infusionin Day0, Day14±1 day, Day28±1 day, Day42±3 days,Day84±3 days, Day126±3 days, Day168±3 days after TIL infusion, and at early withdrawal visit.
ADA
Tidsramme: Within 30 minutes prior to TIL infusion in Day0, at Day7±1 day, Day14±1 day, Day28±1 day, and Day42±3 day after TIL infusion.

Anti-drug antibody (ADA) assessments were performed to evaluate the immunogenicity of the study drug.

Within 30 minutes prior to TIL infusion in Day0, at Day7±1 day, Day14±1 day, Day28±1 day, and Day42±3 day after TIL infusion.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. april 2025

Primær færdiggørelse (Anslået)

1. december 2027

Studieafslutning (Anslået)

1. december 2029

Datoer for studieregistrering

Først indsendt

16. januar 2026

Først indsendt, der opfyldte QC-kriterier

16. november 2026

Først opslået (Faktiske)

18. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner